Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21,924 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors.
Sato J, Shimizu T, Koyama T, Iwasa S, Shimomura A, Kondo S, Kitano S, Yonemori K, Fujiwara Y, Tamura K, Suzuki T, Takase T, Nagai R, Yamaguchi K, Semba T, Zhao ZM, Ren M, Yamamoto N. Sato J, et al. Among authors: suzuki t. Clin Cancer Res. 2022 May 2;28(9):1783-1791. doi: 10.1158/1078-0432.CCR-21-3518. Clin Cancer Res. 2022. PMID: 35180771 Free PMC article. Clinical Trial.
Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer.
Kiyota N, Schlumberger M, Muro K, Ando Y, Takahashi S, Kawai Y, Wirth L, Robinson B, Sherman S, Suzuki T, Fujino K, Gupta A, Hayato S, Tahara M. Kiyota N, et al. Among authors: suzuki t. Cancer Sci. 2015 Dec;106(12):1714-21. doi: 10.1111/cas.12826. Epub 2015 Nov 2. Cancer Sci. 2015. PMID: 26426092 Free PMC article. Clinical Trial.
A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.
Zheng X, Xu Z, Ji Q, Ge M, Shi F, Qin J, Wang F, Chen G, Zhang Y, Huang R, Tan J, Huang T, Li S, Lv Z, Lin Y, Guo Z, Kubota T, Suzuki T, Ikezawa H, Gao M. Zheng X, et al. Among authors: suzuki t. Clin Cancer Res. 2021 Oct 15;27(20):5502-5509. doi: 10.1158/1078-0432.CCR-21-0761. Epub 2021 Jul 29. Clin Cancer Res. 2021. PMID: 34326132 Free PMC article. Clinical Trial.
Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial.
Kiyota N, Tahara M, Robinson B, Schlumberger M, Sherman SI, Leboulleux S, Lee EK, Suzuki T, Ren M, Fushimi K, Wirth LJ. Kiyota N, et al. Among authors: suzuki t. Cancer. 2022 Jun 15;128(12):2281-2287. doi: 10.1002/cncr.34181. Epub 2022 Apr 5. Cancer. 2022. PMID: 35380178 Free PMC article. Clinical Trial.
Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.
Masuda N, Ono M, Mukohara T, Yasojima H, Shimoi T, Kobayashi K, Harano K, Mizutani M, Tanioka M, Takahashi S, Kogawa T, Suzuki T, Okumura S, Takase T, Nagai R, Semba T, Zhao ZM, Ren M, Yonemori K. Masuda N, et al. Among authors: suzuki t. Eur J Cancer. 2022 Jun;168:108-118. doi: 10.1016/j.ejca.2022.03.004. Epub 2022 Apr 29. Eur J Cancer. 2022. PMID: 35500404 Free article. Clinical Trial.
Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer.
Udagawa H, Takahashi S, Hirao M, Tahara M, Iwasa S, Sato Y, Hamakawa T, Shitara K, Horinouchi H, Chin K, Masuda N, Suzuki T, Okumura S, Takase T, Nagai R, Yonemori K. Udagawa H, et al. Among authors: suzuki t. Cancer Med. 2023 Jan;12(2):1269-1278. doi: 10.1002/cam4.4996. Epub 2022 Jul 21. Cancer Med. 2023. PMID: 35864593 Free PMC article.
Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort.
Shitara K, Hirao M, Iwasa S, Oshima T, Komatsu Y, Kawazoe A, Sato Y, Hamakawa T, Yonemori K, Machida N, Yuki S, Suzuki T, Okumura S, Takase T, Semba T, Zimmermann B, Teng A, Yamaguchi K. Shitara K, et al. Among authors: suzuki t. Clin Cancer Res. 2023 Apr 14;29(8):1460-1467. doi: 10.1158/1078-0432.CCR-22-3027. Clin Cancer Res. 2023. PMID: 36730323 Free PMC article. Clinical Trial.
Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.
Ida H, Shimizu T, Nishino M, Nakamura Y, Yazaki S, Katsuya Y, Sato J, Koyama T, Iwasa S, Sudo K, Kondo S, Yonemori K, Shitara K, Shiono S, Matsuoka D, Yasuda K, Otake Y, Suzuki T, Takase T, Takashima S, Yamaguchi K, Semba T, Yamamoto N. Ida H, et al. Among authors: suzuki t. Cancer Res Commun. 2023 Jul 10;3(7):1189-1199. doi: 10.1158/2767-9764.CRC-22-0401. eCollection 2023 Jul. Cancer Res Commun. 2023. PMID: 37435605 Free PMC article. Clinical Trial.
21,924 results
You have reached the last available page of results. Please see the User Guide for more information.